Literature DB >> 12816349

Nuclear import of the pre-integration complex (PIC): the Achilles heel of HIV?

S C Piller1, L Caly, D A Jans.   

Abstract

Current treatments against the Aquired immune deficiency syndrome (AIDS) are reasonably effective in reducing the amount of human immunodeficiency virus (HIV) present in infected patients, but their side-effects, and the emergence of drug-resistant HIV strains have intensified the renewed search for novel anti-HIV therapies. An essential step in HIV infection is the integration of the viral genome into the host cell chromosomes within the nucleus. Unlike other retroviruses, HIV can transport its genetic material, in the form of the large nucleoprotein pre-integration complex (PIC), into the nucleus through the intact nuclear envelope (NE). This enables HIV to infect non-dividing cells such as macrophages and microglial cells. Detailed knowledge of the signal-dependent pathways by which cellular proteins and RNAs cross the NE has accumulated in the past decade, but although several different components of the PIC have been implicated in its nuclear import, the mechanism of nuclear entry remains unclear. Since specifically inhibiting PIC nuclear import would undoubtedly block HIV infection in non-dividing cells, this critical step of HIV replication is of great interest as a drug target. This review examines the complex and controversial literature regarding three PIC components--the HIV proteins matrix, integrase and Vpr--proposed to facilitate PIC nuclear import, and existing models of HIV PIC nuclear import. It also suggests approaches to move towards a better understanding of PIC nuclear import, through examining the role of individual PIC components in the context of the intact PIC by direct visualisation, in order to develop new anti-HIV therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816349     DOI: 10.2174/1389450033490984

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  23 in total

1.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

2.  HIV-1 integrase is capable of targeting DNA to the nucleus via an importin alpha/beta-dependent mechanism.

Authors:  Anna C Hearps; David A Jans
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

3.  Proteolytic cleavage of HIV-1 GFP-Vpr fusions at novel sites within virions and living cells: concerns for intracellular trafficking studies.

Authors:  Leon Caly; David A Jans; Sabine C Piller
Journal:  J Fluoresc       Date:  2008-12-07       Impact factor: 2.217

Review 4.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

5.  The HIV-1 integrase mutant R263A/K264A is 2-fold defective for TRN-SR2 binding and viral nuclear import.

Authors:  Stéphanie De Houwer; Jonas Demeulemeester; Wannes Thys; Susana Rocha; Lieve Dirix; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

6.  Reverse transcription complex: the key player of the early phase of HIV replication.

Authors:  Sergey Iordanskiy; Michael Bukrinsky
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

Review 7.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

8.  Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.

Authors:  Omar Haffar; Larisa Dubrovsky; Richard Lowe; Reem Berro; Fatah Kashanchi; Jeffrey Godden; Christophe Vanpouille; Jürgen Bajorath; Michael Bukrinsky
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.

Authors:  Sapna Sinha; Duane P Grandgenett
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells.

Authors:  Naomi Tsurutani; Jiro Yasuda; Naoki Yamamoto; Byung-Il Choi; Motohiko Kadoki; Yoichiro Iwakura
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.